Skip to content
Disclosery

5AM Venture Management, LLC

Follow

13F filer, CIK 1799883, SAN FRANCISCO, CA

5AM Venture Management, LLC reported $360,208,609 across 20 holdings for the quarter ended 2026-03-31, in a 13F-HR filed 2026-05-15. Its ten largest share positions make up 79.82% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001799883-26-000002

Period
2026-03-31
Reported value
$360M
Holdings
20
Top 10 weight
79.82%
New
2
Sold out
3

Largest buys vs the previous quarter

SecurityShares changeApprox. value
ALXOnew+3,057,325$6.13M
RLYBnew+291,788$2.62M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ERASreduced-1,919,433-$31.1M
VRDNexited-736,595-$22.9M
ELVNexited-772,477-$11.9M
RALLYBIO CORPexited-3,630,724-$2.49M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2026

Share positions as resolved from 13F-HR 0001799883-26-000002, largest first. % of portfolio is the value over $360,208,609, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ERASERASCA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 5,405,404 shares; 2024Q4: 5,405,404 shares; 2025Q1: 5,405,404 shares; 2025Q2: 5,405,404 shares; 2025Q3: 5,405,404 shares; 2025Q4: 5,405,404 shares; 2026Q1: 3,485,971 shares 3,485,971$56.4M15.66%-1,919,433Timeline
TRDAENTRADA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 4,408,379 shares; 2024Q4: 4,408,379 shares; 2025Q1: 4,408,379 shares; 2025Q2: 4,308,379 shares; 2025Q3: 4,256,379 shares; 2025Q4: 4,056,379 shares; 2026Q1: 4,056,379 shares 4,056,379$51.2M14.21%0Timeline
TYRATYRA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 939,298 shares; 2024Q4: 939,298 shares; 2025Q1: 939,298 shares; 2025Q2: 939,298 shares; 2025Q3: 939,298 shares; 2025Q4: 1,029,298 shares; 2026Q1: 1,029,298 shares 1,029,298$39.4M10.94%0Timeline
CAMPCAMP4 THERAPEUTICS CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 2,927,915 shares; 2025Q1: 2,927,915 shares; 2025Q2: 2,927,915 shares; 2025Q3: 5,869,091 shares; 2025Q4: 5,869,091 shares; 2026Q1: 5,869,091 shares 5,869,091$25.9M7.19%0Timeline
CNTACENTESSA PHARMACEUTICALS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,285,000 shares; 2024Q4: 830,945 shares; 2025Q1: 830,945 shares; 2025Q2: 830,945 shares; 2025Q3: 680,945 shares; 2025Q4: 580,945 shares; 2026Q1: 580,945 shares 580,945$23.1M6.41%0Timeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 797,600 shares; 2024Q4: 797,600 shares; 2025Q1: 797,600 shares; 2025Q2: 797,600 shares; 2025Q3: 797,600 shares; 2025Q4: 797,600 shares; 2026Q1: 797,600 shares 797,600$22.5M6.26%0Timeline
MPLTMAPLIGHT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 950,011 shares; 2026Q1: 950,011 shares 950,011$19.3M5.36%0Timeline
TECXTECTONIC THERAPEUTIC INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 646,524 shares; 2024Q4: 596,660 shares; 2025Q1: 511,660 shares; 2025Q2: 511,660 shares; 2025Q3: 511,660 shares; 2025Q4: 606,660 shares; 2026Q1: 606,660 shares 606,660$18.8M5.21%0Timeline
CLDXCELLDEX THERAPEUTICS INC NEWQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 497,270 shares; 2024Q4: 497,270 shares; 2025Q1: 497,270 shares; 2025Q2: 497,270 shares; 2025Q3: 497,270 shares; 2025Q4: 497,270 shares; 2026Q1: 497,270 shares 497,270$15.8M4.38%0Timeline
ARTVARTIVA BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 2,353,304 shares; 2024Q4: 2,353,304 shares; 2025Q1: 2,353,304 shares; 2025Q2: 2,353,304 shares; 2025Q3: 2,353,304 shares; 2025Q4: 2,353,304 shares; 2026Q1: 2,353,304 shares 2,353,304$15.2M4.21%0Timeline
EYPTEYEPOINT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,050,000 shares; 2024Q4: 1,050,000 shares; 2025Q1: 1,050,000 shares; 2025Q2: 1,050,000 shares; 2025Q3: 1,050,000 shares; 2025Q4: 1,050,000 shares; 2026Q1: 1,050,000 shares 1,050,000$13.5M3.76%0Timeline
SRZNSURROZEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 310,000 shares; 2025Q2: 310,000 shares; 2025Q3: 310,000 shares; 2025Q4: 387,500 shares; 2026Q1: 387,500 shares 387,500$11.3M3.13%0Timeline
ZNTLZENTALIS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 490,000 shares; 2024Q4: 490,000 shares; 2025Q1: 490,000 shares; 2025Q2: 490,000 shares; 2025Q3: 490,000 shares; 2025Q4: 3,947,913 shares; 2026Q1: 3,947,913 shares 3,947,913$9.24M2.56%0Timeline
GHRSGH RESEARCH PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 572,665 shares; 2024Q4: 572,665 shares; 2025Q1: 572,665 shares; 2025Q2: 572,665 shares; 2025Q3: 572,665 shares; 2025Q4: 572,665 shares; 2026Q1: 572,665 shares 572,665$8.05M2.24%0Timeline
TARAPROTARA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 800,000 shares; 2025Q1: 800,000 shares; 2025Q2: 800,000 shares; 2025Q3: 800,000 shares; 2025Q4: 1,369,782 shares; 2026Q1: 1,369,782 shares 1,369,782$7.14M1.98%0Timeline
BHVNBIOHAVEN LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 478,972 shares; 2024Q4: 478,972 shares; 2025Q1: 478,972 shares; 2025Q2: 478,972 shares; 2025Q3: 478,972 shares; 2025Q4: 738,972 shares; 2026Q1: 738,972 shares 738,972$6.25M1.74%0Timeline
ALXOALX ONCOLOGY HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 3,057,325 shares 3,057,325$6.13M1.7%newTimeline
SKYESKYE BIOSCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 9,913,168 shares; 2024Q4: 9,913,168 shares; 2025Q1: 9,913,168 shares; 2025Q2: 9,913,168 shares; 2025Q3: 9,681,763 shares; 2025Q4: 9,681,763 shares; 2026Q1: 9,681,763 shares 9,681,763$5.95M1.65%0Timeline
RLYBRALLYBIO CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 291,788 shares 291,788$2.62M0.73%newTimeline
SLNSILENCE THERAPEUTICS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 476,200 shares; 2024Q4: 476,200 shares; 2025Q1: 476,200 shares; 2025Q2: 476,200 shares; 2025Q3: 476,200 shares; 2025Q4: 476,200 shares; 2026Q1: 476,200 shares 476,200$2.51M0.7%0Timeline

Sold out in Q1 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
VRDNVIRIDIAN THERAPEUTICS INC736,595$22.9Mshares
ELVNENLIVEN THERAPEUTICS INC772,477$11.9Mshares
RALLYBIO CORPRALLYBIO CORP3,630,724$2.49Mshares

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001799883-26-000002 base2026-05-15acceptance time not in the bulk data set